| BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases. | BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.
Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, Playa-Albinyana H, Buhler MM, Clot G, Duran-Ferrer M, Lu J, Granada I, Baptista MJ, Navarro JT, Espinet B, Puiggros A, Tapia G, Bandiera L, De Canal G, Bonoldi E, Climent F, Ribera-Cortada I, Fernandez-Caballero M, De la Banda E, Do Nascimento J, Pineda A, Vela D, Rozman M, Aymerich M, Syrykh C, Brousset P, Perera M, Yanez L, Ortin JX, Tuset E, Zenz T, Cook JR, Swerdlow SH, Martin-Subero JI, Colomer D, Matutes E, Bea S, Costa D, Nadeu F, Campo E., Free PMC Article | 02/2/2024 |
| Bcl-3 regulates T cell function through energy metabolism. | Bcl-3 regulates T cell function through energy metabolism.
Liu H, Zeng L, Pan M, Huang L, Li H, Liu M, Niu X, Zhang C, Wang H., Free PMC Article | 11/13/2023 |
| Hsa_circ_0088036 promotes nonsmall cell lung cancer progression by regulating miR-1343-3p/Bcl-3 axis through TGFbeta/Smad3/EMT signaling. | Hsa_circ_0088036 promotes nonsmall cell lung cancer progression by regulating miR-1343-3p/Bcl-3 axis through TGFβ/Smad3/EMT signaling.
Ge P, Chen X, Liu J, Jing R, Zhang X, Li H. | 06/18/2023 |
| Hepatocyte Bcl-3 protects from death-receptor mediated apoptosis and subsequent acute liver failure. | Hepatocyte Bcl-3 protects from death-receptor mediated apoptosis and subsequent acute liver failure.
Gehrke N, Wörns MA, Mann A, Hövelmeyer N, Waisman A, Straub BK, Galle PR, Schattenberg JM., Free PMC Article | 06/11/2022 |
| Bcl-3: A Double-Edged Sword in Immune Cells and Inflammation. | Bcl-3: A Double-Edged Sword in Immune Cells and Inflammation.
Liu H, Zeng L, Yang Y, Guo C, Wang H., Free PMC Article | 04/16/2022 |
| Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. | Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes.
Ai J, Wörmann SM, Görgülü K, Vallespinos M, Zagorac S, Alcala S, Wu N, Kabacaoglu D, Berninger A, Navarro D, Kaya-Aksoy E, Ruess DA, Ciecielski KJ, Kowalska M, Demir IE, Ceyhan GO, Heid I, Braren R, Riemann M, Schreiner S, Hofmann S, Kutschke M, Jastroch M, Slotta-Huspenina J, Muckenhuber A, Schlitter AM, Schmid RM, Steiger K, Diakopoulos KN, Lesina M, Sainz B Jr, Algül H. | 10/30/2021 |
| Bcl-3 promotes Wnt signaling by maintaining the acetylation of beta-catenin at lysine 49 in colorectal cancer. | Bcl-3 promotes Wnt signaling by maintaining the acetylation of β-catenin at lysine 49 in colorectal cancer.
Chen X, Wang C, Jiang Y, Wang Q, Tao Y, Zhang H, Zhao Y, Hu Y, Li C, Ye D, Liu D, Jiang W, Chin EY, Chen S, Liu Y, Wang M, Liu S, Zhang X., Free PMC Article | 10/9/2021 |
| PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3. | PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3.
Sun D, Zhao Y, Wang W, Guan C, Hu Z, Liu L, Jiang X. | 07/24/2021 |
| Bcl-3 promotes multi-modal tumour cell migration via NF-kappaB1 mediated regulation of Cdc42. | Bcl-3 promotes multi-modal tumour cell migration via NF-κB1 mediated regulation of Cdc42.
Turnham DJ, Yang WW, Davies J, Varnava A, Ridley AJ, Conlan RS, Clarkson RWE. | 07/10/2021 |
| BCL-3 and beta-catenin signaling and tumor staging in colorectal cancer. | BCL-3 and β-catenin signaling and tumor staging in colorectal cancer.
Zhang S, Yin C. | 06/5/2021 |
| MicroRNA-627-5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator. | MicroRNA-627-5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator.
Wang J, Chen T, Wang L, Yao B, Sun L, Chen S, Liu Q. | 05/8/2021 |
| BCL3 promotes cyclooxygenase2/prostaglandin E2 signalling in colorectal cancer. | BCL‑3 promotes cyclooxygenase‑2/prostaglandin E2 signalling in colorectal cancer.
Collard TJ, Fallatah HM, Greenhough A, Paraskeva C, Williams AC. | 02/13/2021 |
| The role of B-Cell Lymphoma-3 (BCL-3) in enabling the hallmarks of cancer: implications for the treatment of colorectal carcinogenesis. | The role of B-Cell Lymphoma-3 (BCL-3) in enabling the hallmarks of cancer: implications for the treatment of colorectal carcinogenesis.
Legge DN, Chambers AC, Parker CT, Timms P, Collard TJ, Williams AC., Free PMC Article | 08/22/2020 |
| Approximately 3% of all newly diagnosed chronic lymphocytic leukemia patients have either an IGH-BCL2 or IGH-BCL3 translocations. | IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.
Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA., Free PMC Article | 12/28/2019 |
| BCL-3 might be a useful indicator of glioma response to alkylating chemotherapy. | BCL3 expression promotes resistance to alkylating chemotherapy in gliomas.
Wu L, Bernal GM, Cahill KE, Pytel P, Fitzpatrick CA, Mashek H, Weichselbaum RR, Yamini B., Free PMC Article | 10/5/2019 |
| BCL-3 acts as a driver of the stem cell phenotype in colorectal cancer cells, potentially promoting tumour cell plasticity and therapeutic resistance. | BCL-3 promotes a cancer stem cell phenotype by enhancing β-catenin signalling in colorectal tumour cells.
Legge DN, Shephard AP, Collard TJ, Greenhough A, Chambers AC, Clarkson RW, Paraskeva C, Williams AC., Free PMC Article | 08/17/2019 |
| these findings indicated that BCL3 appeared as a promising molecular biomarker of pediatric acute myeloid leukemia with unfavorable prognosis | BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.
Niu Y, Yang X, Chen Y, Zhang L, Jin X, Tang Y, Li L, Yu L, Guo Y, Wang H., Free PMC Article | 06/15/2019 |
| Data suggest that B cell lymphoma 3 (Bcl-3) may be a potential clinical biomarker for diagnosis, treatment, and prognosis of patients with BL1-subtype triple-negative breast cancer (TNBC). | Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells.
Huo J, Chen X, Zhang H, Hu Y, Jiang Y, Liu S, Zhang X. | 03/16/2019 |
| This work identifies PD-L1 as a novel target of Bcl3, and links Bcl3 to IFN-gamma signaling and PD-L1-mediated immune escape. | The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
Zou Y, Uddin MM, Padmanabhan S, Zhu Y, Bu P, Vancura A, Vancurova I., Free PMC Article | 03/9/2019 |
| BCL-3 transcription is regulated directly by NF-KB signaling in colorectal cancer | Alternative NF-κB signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3.
Tao Y, Liu Z, Hou Y, Wang S, Liu S, Jiang Y, Tan D, Ge Q, Li C, Hu Y, Liu Z, Chen X, Wang Q, Wang M, Zhang X. | 03/2/2019 |
| Bcl3 overexpression could be a surrogate biomarker for NF-kappaB activation in Barrett's epithelial cells leading to deregulation of NF-kappaB-inducible gene expression, inferring resistance to apoptosis through the activation of anti-apoptotic genes such as Survivin. | Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-κB activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence.
Puccio I, Khan S, Butt A, Graham D, Sehgal V, Patel D, Novelli M, Lovat LB, Rodriguez-Justo M, Hamoudi RA., Free PMC Article | 12/1/2018 |
| Data show that B-cell CLL-lymphoma 3 (Bcl-3) expression levels in colonic T cells correlate with disease manifestation in patients with inflammatory bowel disease. | Elevated levels of Bcl-3 inhibits Treg development and function resulting in spontaneous colitis.
Reißig S, Tang Y, Nikolaev A, Gerlach K, Wolf C, Davari K, Gallus C, Masri J, Mufazalov IA, Neurath MF, Wunderlich FT, Schattenberg JM, Galle PR, Weigmann B, Waisman A, Glasmacher E, Hövelmeyer N., Free PMC Article | 12/1/2018 |
| Bcl-3 participates in the IL-22-induced expression of STAT3-dependent late-response genes, and the combination of IL-22 and IL-17-induced psoriasis-related gene expression. | Bcl-3 induced by IL-22 via STAT3 activation acts as a potentiator of psoriasis-related gene expression in epidermal keratinocytes.
Tohyama M, Shirakata Y, Hanakawa Y, Dai X, Shiraishi K, Murakami M, Miyawaki S, Mori H, Utsunomiya R, Masuda K, Hashimoto K, Sayama K. | 11/10/2018 |
| B-cell leukemia protein 3 (Bcl3) expressed in response to cytokine TWEAK stimulation (experimental kidney injury) decreases TWEAK-induced inflammatory and lethal responses. | Bcl3: a regulator of NF-κB inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells.
Poveda J, Sanz AB, Carrasco S, Ruiz-Ortega M, Cannata-Ortiz P, Sanchez-Niño MD, Ortiz A., Free PMC Article | 04/14/2018 |
| Four gene signature (PTEN, PIK3C2A, ITPA and BCL3) is an independent prognostic factors of both overall survival and disease-free survival in clear-cell renal-cell carcinoma. | A four-gene signature predicts survival in clear-cell renal-cell carcinoma.
Dai J, Lu Y, Wang J, Yang L, Han Y, Wang Y, Yan D, Ruan Q, Wang S., Free PMC Article | 02/24/2018 |